The Up-Regulation of Oxidative Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment.
Animals
Antineoplastic Agents
/ therapeutic use
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cell Transformation, Neoplastic
/ drug effects
Flow Cytometry
G1 Phase Cell Cycle Checkpoints
/ drug effects
Glioblastoma
/ drug therapy
Humans
Membrane Potential, Mitochondrial
/ drug effects
Monoamine Oxidase
/ metabolism
Monoamine Oxidase Inhibitors
/ therapeutic use
Oxidative Stress
/ drug effects
Rats
Reactive Oxygen Species
/ metabolism
Glioblastoma
MAO-B inhibitors
migration
oxidative stress
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 May 2019
25 May 2019
Historique:
received:
24
04
2019
revised:
22
05
2019
accepted:
23
05
2019
entrez:
28
5
2019
pubmed:
28
5
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Gliomas are malignant brain tumors characterized by rapid spread and growth into neighboring tissues and graded I-IV by the World Health Organization. Glioblastoma is the fastest growing and most devastating IV glioma. The aim of this paper is to evaluate the biological effects of two potent and selective Monoamine Oxidase B (MAO-B) inhibitors, Cmp
Identifiants
pubmed: 31130597
pii: molecules24102005
doi: 10.3390/molecules24102005
pmc: PMC6572653
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Monoamine Oxidase Inhibitors
0
Reactive Oxygen Species
0
Monoamine Oxidase
EC 1.4.3.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Blood. 2000 Jan 1;95(1):189-97
pubmed: 10607702
Curr Med Chem. 2004 Aug;11(15):1965-82
pubmed: 15279561
Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93
pubmed: 16860996
Cancer Cell. 2006 Sep;10(3):175-6
pubmed: 16959608
Neurochem Int. 2008 Jan;52(1-2):230-4
pubmed: 17624626
Carcinogenesis. 2009 Jan;30(1):93-100
pubmed: 18952595
Mutat Res. 2013 Jan-Mar;752(1):10-24
pubmed: 22940039
Oncol Rep. 2013 Oct;30(4):1587-92
pubmed: 23900512
Biochim Biophys Acta. 2014 Aug;1846(1):113-20
pubmed: 24657728
Toxicol Lett. 2015 Jan 22;232(2):349-55
pubmed: 25448282
Redox Biol. 2015 Dec;6:334-343
pubmed: 26335399
PLoS One. 2015 Oct 08;10(10):e0140131
pubmed: 26447477
Int J Oncol. 2016 Feb;48(2):559-68
pubmed: 26648123
Anticancer Agents Med Chem. 2016;16(9):1190-7
pubmed: 26845134
Sci Rep. 2016 Mar 04;6:22455
pubmed: 26940200
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Front Pharmacol. 2016 Oct 18;7:340
pubmed: 27803666
Neoplasia. 2017 Apr;19(4):364-373
pubmed: 28319810
BMC Cancer. 2017 Jun 20;17(1):434
pubmed: 28633655
Oncol Rep. 2017 Oct;38(4):2033-2042
pubmed: 28849217
Oncotarget. 2017 Apr 16;8(31):51888-51906
pubmed: 28881698
Technol Cancer Res Treat. 2018 Jan 1;17:1533034618770305
pubmed: 29756546
J BUON. 2018 Nov-Dec;23(6):1840-1845
pubmed: 30610811
J Enzyme Inhib Med Chem. 2019 Dec;34(1):597-612
pubmed: 30727777